MetaVia Inc MTVA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity
-
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum
-
MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential
-
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
-
MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH
-
MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH
-
MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update
-
MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026
Trading Information
- Previous Close Price
- $1.73
- Day Range
- $1.65–1.80
- 52-Week Range
- $0.97–19.03
- Bid/Ask
- $1.70 / $1.80
- Shares Outstanding
- 5.16M
- Market Cap
- $9.19M
- Volume/Avg
- 133,483 / 4M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
- Website
- https://www.metaviatx.com
Valuation
|
Metric
|
MTVA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.90 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
MTVA
Financial Strength
|
Metric
|
MTVA
|
|---|---|
Quick Ratio | 2.64 |
Current Ratio | 2.73 |
Interest Coverage | — |
Quick Ratio
MTVA
Profitability
|
Metric
|
MTVA
|
|---|---|
Return on Assets (Normalized) | −91.73% |
Return on Equity (Normalized) | −187.11% |
Return on Invested Capital (Normalized) | −190.01% |
Return on Assets
MTVA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|h%CSpx | LOCK|D&P< | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|J^^S^&@ | LOCK|R%Sw | $70B | |||
| argenx SE ADR
ARGX
| LOCK|^&?Fhv | LOCK|qm | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!#?r^h | LOCK|s>T< | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|R%>$R# | LOCK|FF | $36B | |||
| Moderna Inc
MRNA
| LOCK|!%HPM% | LOCK|!q | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|#&j!%CsK | LOCK|#^W! | $25B | |||
| Incyte Corp
INCY
| LOCK|ks#DvbD | LOCK|<s< | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|v<FBBrP | LOCK|w^M | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|@S$VrC | LOCK|%@Q | $17B |
United States